Literature DB >> 35851999

Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment.

Eleni Karatza1, Apostolos Papachristos2, Gregory B Sivolapenko2, Daniel Gonzalez1.   

Abstract

Therapeutic outcomes in patients with metastatic colorectal cancer (mCRC) receiving bevacizumab treatment are highly variable, and a reliable predictive factor is not available. Progression-free survival (PFS) and overall survival (OS) were recorded from an observational, prospective study after 5 years of follow-up, including 46 patients with mCRC receiving bevacizumab treatment. Three vascular endothelial growth factor (VEGF)-A and two intercellular adhesion molecule-1 genes polymorphisms, age, gender, weight, dosing scheme, and co-treatments were collected. Given the relatively small number of events (37 [80%] for the PFS and 26 [57%] for the OS), to study the effect of these covariates on PFS and OS, a covariate analysis was performed using statistical and supervised machine learning techniques, including Cox regression, penalized Cox regression techniques (least absolute shrinkage and selection operator [LASSO], ridge regression, and elastic net), survival trees, and survival forest. The predictive performance of each method was evaluated in bootstrapped samples, using prediction error curves and the area under the curve of the receiver operating characteristic. The LASSO penalized Cox-regression model showed the best overall performance. Nonlinear mixed effects (NLME) models were developed, and a conventional stepwise covariate search was performed. Then, covariates identified as important by the LASSO model were included in the base NLME models developed for PFS and OS, resulting in improved models as compared to those obtained with the stepwise covariate search. It was shown that having gene polymorphisms in VEGFA (rs699947 and rs1570360) and ICAM1 (rs1799969) are associated with a favorable clinical outcome in patients with mCRC receiving bevacizumab treatment.
© 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35851999      PMCID: PMC9574729          DOI: 10.1002/psp4.12848

Source DB:  PubMed          Journal:  CPT Pharmacometrics Syst Pharmacol        ISSN: 2163-8306


  41 in total

Review 1.  Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology.

Authors:  Sebastien Benzekry
Journal:  Clin Pharmacol Ther       Date:  2020-08-01       Impact factor: 6.875

2.  Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution.

Authors:  Christopher Cox; Haitao Chu; Michael F Schneider; Alvaro Muñoz
Journal:  Stat Med       Date:  2007-10-15       Impact factor: 2.373

3.  Genetic Polymorphisms rs699947, rs1570360, and rs3025039 on the VEGF Gene Are Correlated with Extracranial Internal Carotid Artery Stenosis and Ischemic Stroke.

Authors:  Binod Kumar Yadav; Renu Yadav; Hyuk Chang; Kangho Choi; Joon-Tae Kim; Man Seok Park; Hyun Goo Kang; Insung Choo; Seong Hwan Ahn; Dong Seok Oh; Yeon Soo Ha; Ihngyu Kim; Man-Wook Seo; Byoung-Soo Shin
Journal:  Ann Clin Lab Sci       Date:  2017-03       Impact factor: 1.256

Review 4.  Covariate selection in pharmacometric analyses: a review of methods.

Authors:  Matthew M Hutmacher; Kenneth G Kowalski
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

5.  Population pharmacokinetics of bevacizumab in cancer patients with external validation.

Authors:  Kelong Han; Thomas Peyret; Mathilde Marchand; Angelica Quartino; Nathalie H Gosselin; Sandhya Girish; David E Allison; Jin Jin
Journal:  Cancer Chemother Pharmacol       Date:  2016-06-21       Impact factor: 3.333

6.  Association between E469K polymorphism in the ICAM1 gene and the risk of diabetic nephropathy: a meta-analysis.

Authors:  Liya Liu; Dongling He; Ling Fang; Xiaojie Yan
Journal:  Lipids Health Dis       Date:  2018-12-26       Impact factor: 3.876

7.  Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.

Authors:  Yingmiao Liu; Mark D Starr; Anuradha Bulusu; Herbert Pang; Nan Soon Wong; Wanda Honeycutt; Anthony Amara; Herbert I Hurwitz; Andrew B Nixon
Journal:  Cancer Med       Date:  2013-03-06       Impact factor: 4.452

8.  Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.

Authors:  Fotios Loupakis; Chiara Cremolini; Dongyun Yang; Lisa Salvatore; Wu Zhang; Takeru Wakatsuki; Pierre Bohanes; Marta Schirripa; Leonor Benhaim; Sara Lonardi; Carlotta Antoniotti; Giuseppe Aprile; Francesco Graziano; Annamaria Ruzzo; Sara Lucchesi; Monica Ronzoni; Ferdinando De Vita; Giuseppe Tonini; Alfredo Falcone; Heinz-Josef Lenz
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

9.  How to develop a more accurate risk prediction model when there are few events.

Authors:  Menelaos Pavlou; Gareth Ambler; Shaun R Seaman; Oliver Guttmann; Perry Elliott; Michael King; Rumana Z Omar
Journal:  BMJ       Date:  2015-08-11
View more
  1 in total

1.  Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment.

Authors:  Eleni Karatza; Apostolos Papachristos; Gregory B Sivolapenko; Daniel Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-08-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.